- Home
- KLRS vs CLAR Comparison
KLRS vs CLAR Comparison
Compare KLRS & CLAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- CLAR
- Stock Information
- Founded
- KLRS 2019
- CLAR 1957
- Country
- KLRS United States
- CLAR United States
- Employees
- KLRS N/A
- CLAR N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- CLAR Recreational Games/Products/Toys
- Sector
- KLRS Health Care
- CLAR Consumer Discretionary
- Exchange
- KLRS Nasdaq
- CLAR Nasdaq
- Market Cap
- KLRS 129.0M
- CLAR 136.3M
- IPO Year
- KLRS N/A
- CLAR N/A
- Fundamental
- Price
- KLRS $2.69
- CLAR $3.16
- Analyst Decision
- KLRS Buy
- CLAR Strong Buy
- Analyst Count
- KLRS 1
- CLAR 4
- Target Price
- KLRS N/A
- CLAR $5.50
- AVG Volume (30 Days)
- KLRS 57.0K
- CLAR 128.4K
- Earning Date
- KLRS 08-15-2025
- CLAR 07-31-2025
- Dividend Yield
- KLRS N/A
- CLAR 3.16%
- EPS Growth
- KLRS N/A
- CLAR N/A
- EPS
- KLRS N/A
- CLAR N/A
- Revenue
- KLRS N/A
- CLAR $254,200,000.00
- Revenue This Year
- KLRS N/A
- CLAR N/A
- Revenue Next Year
- KLRS N/A
- CLAR $4.23
- P/E Ratio
- KLRS N/A
- CLAR N/A
- Revenue Growth
- KLRS N/A
- CLAR N/A
- 52 Week Low
- KLRS $2.28
- CLAR $3.02
- 52 Week High
- KLRS $24.15
- CLAR $6.10
- Technical
- Relative Strength Index (RSI)
- KLRS N/A
- CLAR 32.04
- Support Level
- KLRS N/A
- CLAR $3.80
- Resistance Level
- KLRS N/A
- CLAR $3.95
- Average True Range (ATR)
- KLRS 0.00
- CLAR 0.15
- MACD
- KLRS 0.00
- CLAR -0.05
- Stochastic Oscillator
- KLRS 0.00
- CLAR 12.04
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.
About CLAR Clarus Corporation
Clarus Corp is a designer, developer, manufacturer, and distributor of outdoor equipment and lifestyle products focused on the climb, ski, mountain, sport, and skincare markets. The company operates through the Outdoor segment, which includes Black Diamond Equipment and PIEPS, is a world-wide leader in designing, manufacturing, and marketing outdoor engineered equipment and apparel for climbing, mountaineering, trail running, backpacking, skiing, and a wide range of other year-round outdoor recreation activities. The Adventure segment, which includes Rhino-Rack, MAXTRAX and TRED, is a manufacturer of engineered automotive roof racks, trays, mounting systems, luggage boxes, carriers, recovery boards and accessories in Australia and New Zealand and United States.